Currently, there are 91.78M common shares owned by the public and among those 89.71M shares have been available to trade.
The company’s stock has a 5-day price change of -17.82% and -50.91% over the past three months. ACHC shares are trading -45.80% year to date (YTD), with the 12-month market performance down to -69.41% lower. It has a 12-month low price of $23.36 and touched a high of $82.40 over the same period. ACHC has an average intraday trading volume of 2.10 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -21.73%, -32.69%, and -57.15% respectively.
Institutional ownership of Acadia Healthcare Company Inc (NASDAQ: ACHC) shares accounts for 107.96% of the company’s 91.78M shares outstanding.
It has a market capitalization of $1.98B and a beta (3y monthly) value of 1.12. The stock’s trailing 12-month PE ratio is 7.74, while the earnings-per-share (ttm) stands at $2.78. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.72% over the week and 5.74% over the month.
Analysts forecast that Acadia Healthcare Company Inc (ACHC) will achieve an EPS of 0.36 for the current quarter, 0.75 for the next quarter and 3.01 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.33 while analysts give the company a high EPS estimate of 0.33. Comparatively, EPS for the current quarter was 0.84 a year ago. Earnings per share for the fiscal year are expected to decrease by -19.53%, and 13.39% over the next financial year. EPS should shrink at an annualized rate of -0.99% over the next five years, compared to 17.49% over the past 5-year period.
Looking at the support for the ACHC, a number of firms have released research notes about the stock. Barclays stated their Equal Weight rating for the stock in a research note on February 28, 2025, with the firm’s price target at $43-$35. KeyBanc Capital Markets coverage for the Acadia Healthcare Company Inc (ACHC) stock in a research note released on January 07, 2025 offered a Overweight rating with a price target of $70. Deutsche Bank on their part issued Hold rating on April 25, 2024.
